Cell Biology
Learning Objectives
- Understand the fundamental concepts of Cell Biology
- Apply key formulas and techniques to solve problems
- Practice with exam-level questions to build speed and accuracy
What is Cell Biology?
Cell biology is the study of the structure, function, and behavior of cells, the fundamental units of life. For NEET, key topics include cell theory, prokaryotic vs eukaryotic cells, cell organelles (nucleus, mitochondria, ER, Golgi apparatus, ribosomes, lysosomes), cell membrane structure (fluid mosaic model), and cell division (mitosis and meiosis). Understanding the molecular machinery within cells is crucial.
Key Concepts
Cell Theory: All living organisms are composed of cells; the cell is the basic structural and functional unit; all cells arise from pre-existing cells. Cell Membrane: Fluid mosaic model by Singer and Nicolson. Phospholipid bilayer with embedded proteins. Mitochondria: Powerhouse of the cell, site of aerobic respiration, has double membrane with cristae, contains its own DNA. Endoplasmic Reticulum: RER (rough with ribosomes for protein synthesis) and SER (smooth for lipid synthesis). Golgi Apparatus: Modifies, sorts, and packages proteins. Lysosomes: Suicidal bags containing hydrolytic enzymes. Cell Division: Mitosis (equational division for growth) and Meiosis (reduction division for gamete formation).
Solved Examples
a) Nucleus b) Ribosome c) Mitochondria d) Lysosome
a) 2 haploid cells b) 4 haploid cells c) 2 diploid cells d) 4 diploid cells
a) Nucleus b) Mitochondria c) Ribosome d) Golgi apparatus
Shortcut Techniques
- For identifying stages of mitosis: remember PMAT (Prophase, Metaphase, Anaphase, Telophase).
- In meiosis, crossing over occurs during pachytene stage of prophase I.
- Plant cells can be distinguished from animal cells by the presence of cell wall, chloroplasts, and a large central vacuole.
- The endomembrane system includes the ER, Golgi apparatus, lysosomes, and vacuoles (but not mitochondria or chloroplasts).
Application-Based Learning
Connect concepts to real-world applications: Why sky is blue (Rayleigh scattering), how pressure cookers work, why apples turn brown (oxidation).
Problem-Solving Methodology
1) Identify given data. 2) Recall formulas. 3) Check unit consistency. 4) Solve step-by-step. 5) Verify through estimation.
Problem-Solving Methodology
1) Identify given data. 2) Recall formulas. 3) Check unit consistency. 4) Solve step-by-step. 5) Verify through estimation.
Membrane Transport: Passive, Active, and Vesicular Mechanisms
The plasma membrane controls the movement of substances through a combination of passive diffusion, facilitated diffusion, active transport, and vesicular trafficking. Passive diffusion moves small non‑polar molecules (O₂, CO₂, N₂) down their concentration gradient without protein assistance. Facilitated diffusion employs carrier proteins (e.g., GLUT1 for glucose) or channel proteins (e.g., aquaporins for water) to accelerate the flux of polar or charged solutes while still following the electrochemical gradient. Active transport consumes ATP directly (primary active transport) or uses the energy stored in an ion gradient (secondary active transport). The Na⁺/K⁺‑ATPase pumps three Na⁺ out and two K⁺ in per ATP hydrolysed, establishing the steep Na⁺ gradient that drives secondary transporters such as the Na⁺/glucose symporter (SGLT1) in intestinal epithelia. Vesicular transport includes endocytosis (phagocytosis, pinocytosis, receptor‑mediated endocytosis) and exocytosis. Clathrin‑coated pits concentrate specific ligands (e.g., LDL via LDL receptor) before invagination; dynamin GTPase pinches off the vesicle. Lysosomal degradation follows endocytosis, while secretory vesicles fuse with the membrane in a Ca²⁺‑dependent manner mediated by SNARE proteins. The balance between these pathways determines cellular homeostasis, nutrient uptake, and signal termination.
Key Transporters and Their Clinical Relevance
Defects in specific transporters underlie hereditary disorders: cystic fibrosis results from misfolded CFTR chloride channel; familial hypercholesterolemia stems from LDL‑receptor mutations impairing receptor‑mediated endocytosis; and glucose‑galactose malabsorption is caused by SGLT1 loss‑of‑function. Pharmacologically, cardiac glycosides (ouabain, digoxin) inhibit Na⁺/K⁺‑ATPase, increasing intracellular Na⁺ and consequently Ca²⁺ via the Na⁺/Ca²⁺ exchanger, enhancing contractility. Loop diuretics block the Na⁺‑K⁺‑2Cl⁻ cotransporter (NKCC2) in the thick ascending limb, while thiazides inhibit the Na⁺‑Cl⁻ cotransporter (NCC) in the distal convoluted tubule. Understanding the stoichiometry and regulation of these transporters is essential for predicting drug action and side‑effects.
Cell Cycle Checkpoints and Cyclin‑Dependent Kinase Regulation
Progression through the eukaryotic cell cycle is governed by a series of checkpoints that monitor DNA integrity, chromosome alignment, and cell size. The G₁/S checkpoint (restriction point) evaluates growth signals, nutrient status, and DNA damage. In mammalian cells, the retinoblastoma protein (pRb) binds E2F transcription factors; phosphorylation of pRb by cyclin D‑CDK4/6 complexes releases E2F, driving expression of cyclin E and DNA replication genes. DNA damage activates ATM/ATR kinases, which phosphorylate p53, leading to p21 transcription and inhibition of cyclin E‑CDK2, enforcing G₁ arrest. The intra‑S checkpoint monitors replication fork stability; ATR‑Chk1 signaling stalls origin firing and stabilizes forks. The G₂/M checkpoint prevents entry into mitosis with unrepaired DNA; cyclin B‑CDK1 (also known as Cdc2) is kept inactive by Wee1‑mediated phosphorylation on Tyr15. Activation requires Cdc25 phosphatase removal of this inhibitory phosphate, a step blocked by Chk1/Chk2 in response to DNA lesions. The spindle assembly checkpoint (SAC) operates during metaphase: unattached kinetochores generate the mitotic checkpoint complex (MCC) that inhibits the anaphase‑promoting complex/cyclosome (APC/C), preventing securin and cyclin B degradation. Only when all chromosomes achieve bipolar attachment does the SAC silence, allowing separase to cleave cohesin and initiate anaphase. Dysregulation of any checkpoint contributes to genomic instability and carcinogenesis.
Cyclin‑CDK Complex Specificity and Inhibitors
Cyclins confer substrate specificity and temporal expression: D‑type cyclins (D1, D2, D3) respond to mitogenic signals; cyclin E peaks at G₁/S; cyclin A functions in S and G₂; cyclin B drives M phase. CDK inhibitors (CKIs) are classified into INK4 family (p16^INK4a, p15, p18, p19) that bind CDK4/6 exclusively, and CIP/KIP family (p21^CIP1, p27^KIP1, p57^KIP2) that inhibit multiple cyclin‑CDK complexes. p21 is a transcriptional target of p53, linking DNA damage to cell‑cycle arrest. p27 accumulates in quiescent cells and is degraded via SCF^Skp2 ubiquitin ligase upon mitogenic stimulation. Therapeutically, CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are approved for hormone‑receptor‑positive breast cancer, exploiting the dependence of these tumours on cyclin D‑CDK4/6 activity.
Enzyme Kinetics: Michaelis‑Menten, Allosteric Regulation, and Inhibition Types
Enzyme catalysis is quantified by the Michaelis‑Menten equation: v = (Vmax × [S]) / (Km + [S]), where Vmax = kcat × [E]total and Km is the substrate concentration at half‑maximal velocity. kcat (turnover number) reflects the catalytic efficiency per active site. The ratio kcat/Km defines the specificity constant, indicating how effectively an enzyme captures and converts substrate at low concentrations. Lineweaver‑Burk double‑reciprocal plots (1/v vs 1/[S]) linearize the data: y‑intercept = 1/Vmax, x‑intercept = –1/Km. However, this transformation exaggerates error at low [S]; Eadie‑Hofstee (v vs v/[S]) and Hanes‑Woolf ([S]/v vs [S]) plots provide more reliable parameter estimation. Allosteric enzymes deviate from hyperbolic kinetics, displaying sigmoidal v vs [S] curves described by the Hill equation: v = Vmax × [S]^n / (K0.5^n + [S]^n), where n (Hill coefficient) > 1 indicates positive cooperativity. Classic examples include aspartate transcarbamoylase (ATCase) regulated by CTP (inhibitor) and ATP (activator), and phosphofructokinase‑1 (PFK‑1) activated by AMP/Fructose‑2,6‑bisphosphate and inhibited by ATP/citrate. Inhibition patterns: competitive inhibitors increase apparent Km without affecting Vmax (lines intersect on y‑axis); non‑competitive inhibitors decrease Vmax with unchanged Km (lines intersect on x‑axis); uncompetitive inhibitors lower both Vmax and Km proportionally (parallel lines); mixed inhibition alters both parameters unequally. Irreversible inhibitors (e.g., aspirin acetylating COX‑1) covalently modify the enzyme, reducing active enzyme concentration. Understanding these patterns enables prediction of metabolic flux changes under physiological and pharmacological conditions.
Regulation by Covalent Modification and Protein‑Protein Interaction
Many metabolic enzymes are regulated by phosphorylation/dephosphorylation cycles. Glycogen phosphorylase is activated by phosphorylase kinase (itself activated by PKA) and inactivated by protein phosphatase‑1 (PP1). Hormonal signals (glucagon, epinephrine) raise cAMP, activating PKA, which phosphorylates both phosphorylase kinase and glycogen synthase (inactivating the latter). Conversely, insulin activates PP1 via the PI3K‑Akt pathway, promoting glycogen synthesis. Pyruvate dehydrogenase complex (PDC) is inactivated by pyruvate dehydrogenase kinases (PDKs) and reactivated by pyruvate dehydrogenase phosphatases (PDPs). High NADH/NAD⁺ and acetyl‑CoA/CoA ratios stimulate PDKs, linking energy status to glucose oxidation. These covalent switches provide rapid, reversible control without new protein synthesis.
Integration of Carbohydrate, Lipid, and Amino Acid Metabolism
Central carbon metabolism converges at acetyl‑CoA, the hub linking glycolysis, fatty‑acid β‑oxidation, ketogenesis, and the tricarboxylic acid (TCA) cycle. In the fed state, high insulin promotes glycolysis, pyruvate dehydrogenase activity, and de novo lipogenesis via acetyl‑CoA carboxylase (ACC) and fatty‑acid synthase (FAS). Citrate exported from mitochondria activates ACC and inhibits PFK‑1, coordinating fatty‑acid synthesis with glycolytic flux. During fasting, glucagon and low insulin stimulate lipolysis in adipose tissue, releasing free fatty acids that undergo β‑oxidation in liver mitochondria, generating acetyl‑CoA, NADH, and FADH₂. Excess acetyl‑CoA exceeds TCA capacity (due to low oxaloacetate diverted to gluconeogenesis) and is diverted to ketogenesis (HMG‑CoA synthase, HMG‑CoA lyase) producing acetoacetate and β‑hydroxybutyrate for peripheral tissues. Amino acid catabolism feeds into the TCA cycle at multiple entry points: alanine → pyruvate; glutamate → α‑ketoglutarate; aspartate → oxaloacetate; branched‑chain amino acids → succinyl‑CoA and acetyl‑CoA. The glucose‑alanine cycle transports nitrogen from muscle to liver while providing gluconeogenic substrate. Transamination reactions require pyridoxal phosphate (vitamin B₆). The urea cycle disposes of excess nitrogen, consuming aspartate and generating fumarate, which re‑enters the TCA cycle. Metabolic integration is further modulated by allosteric effectors (AMP, ATP, citrate, acetyl‑CoA) and hormonal signaling (insulin/glucagon, epinephrine, cortisol) that alter enzyme phosphorylation states and gene expression.
Metabolic Flexibility and Pathological States
Metabolic flexibility refers to the ability to switch between fuel sources. Impaired flexibility underlies insulin resistance: chronic lipid oversupply elevates intramyocellular diacylglycerol and ceramides, activating PKCθ and serine‑phosphorylating IRS‑1, blunting insulin signaling. In type 2 diabetes, hepatic gluconeogenesis remains unsuppressed despite hyperglycemia due to defective insulin signaling and elevated glucagon. Cancer cells exhibit the Warburg effect — high glycolysis with lactate production even in oxygen — driven by oncogenic signaling (PI3K/Akt/mTOR, Myc) that upregulates glucose transporters (GLUT1) and glycolytic enzymes (HK2, PKM2). Targeting metabolic enzymes (e.g., IDH1/2 inhibitors in glioma, glutaminase inhibitors in MYC‑driven tumours) exploits these dependencies.
Signal Transduction: G‑Protein Coupled Receptors and Second Messengers
G‑protein coupled receptors (GPCRs) constitute the largest receptor superfamily, transducing extracellular signals (hormones, neurotransmitters, photons, odorants) via heterotrimeric G proteins (Gα, Gβγ). Ligand binding induces a conformational change that promotes GDP‑GTP exchange on Gα, causing dissociation of Gα‑GTP from Gβγ. Both subunits can regulate effectors. Gαs stimulates adenylyl cyclase, raising cAMP; Gαi inhibits adenylyl cyclase, lowering cAMP; Gαq/11 activates phospholipase C‑β (PLCβ), hydrolyzing PIP₂ to IP₃ and DAG. IP₃ triggers Ca²⁺ release from the endoplasmic reticulum via IP₃ receptors; DAG activates protein kinase C (PKC) isoforms. cAMP activates protein kinase A (PKA), which phosphorylates targets such as CREB (cAMP response element‑binding protein), regulating gene transcription. Ca²⁺/calmodulin activates Ca²⁺/calmodulin‑dependent kinases (CaMKs) and calcineurin (a phosphatase). The β‑adrenergic receptor exemplifies Gαs signaling: epinephrine → β‑AR → Gαs → AC → cAMP → PKA → phosphorylase kinase → glycogen phosphorylase activation. Desensitization involves GPCR kinases (GRKs) phosphorylating the activated receptor, recruiting β‑arrestin, which sterically blocks G protein coupling and targets the receptor for clathrin‑mediated endocytosis. β‑arrestin also scaffolds MAPK cascades, providing G protein‑independent signaling. Cross‑talk between pathways (e.g., PKA phosphorylating and inhibiting PLCβ) fine‑tunes cellular responses. Mutations in GPCRs or G proteins cause disease: activating mutations in TSH receptor cause hyperthyroidism; inactivating mutations in V2 vasopressin receptor cause nephrogenic diabetes insipidus; cholera toxin ADP‑ribosylates Gαs, locking it in GTP‑bound state, causing massive cAMP elevation and secretory diarrhea.
Small GTPases and MAPK Cascades
Beyond heterotrimeric G proteins, monomeric small GTPases (Ras, Rho, Rac, Cdc42) act as molecular switches cycling between GTP‑bound active and GDP‑bound inactive states. Guanine nucleotide exchange factors (GEFs) promote activation; GTPase‑activating proteins (GAPs) accelerate intrinsic GTP hydrolysis. Ras activation by receptor tyrosine kinases (RTKs) recruits Raf to the membrane, initiating the MAPK/ERK cascade (Raf → MEK → ERK). ERK phosphorylates transcription factors (Elk‑1, c‑Fos) driving proliferation. Rho family GTPases regulate actin cytoskeleton: RhoA → ROCK → stress fibers; Rac1 → lamellipodia; Cdc42 → filopodia. Dysregulated Ras (e.g., KRAS mutations in pancreatic, colorectal cancers) constitutively activates MAPK and PI3K/Akt pathways. Therapeutic targeting includes farnesyltransferase inhibitors (preventing membrane localization) and downstream MEK inhibitors (trametinib, cobimetinib).
- Confusing competitive inhibition with non‑competitive inhibition by misreading Lineweaver‑Burk intercepts.
- Assuming all allosteric enzymes follow Michaelis‑Menten kinetics; they display sigmoidal curves and require Hill analysis.
- Overlooking that cyclin‑CDK complexes require both cyclin binding and activating phosphorylation (Thr160 on CDK2) for full activity.
- Neglecting the role of the spindle assembly checkpoint in preventing anaphase onset until all kinetochores are attached.
- Treating Gαs and Gαi as interchangeable; they have opposite effects on adenylyl cyclase and cAMP levels.
- Forgetting that irreversible inhibitors reduce the total active enzyme concentration, altering Vmax but not Km in the same way as reversible inhibitors.
- Remember that metabolic integration hinges on shared intermediates like acetyl‑CoA and on hormonal regulation of key phosphorylated enzymes.
Apoptosis and Regulated Necrosis: Intrinsic, Extrinsic, and Non‑Apoptotic Death Pathways
Programmed cell death eliminates unwanted cells without eliciting inflammation. The intrinsic (mitochondrial) pathway is triggered by cellular stress — DNA damage, oxidative stress, growth factor withdrawal — leading to BH3‑only proteins (Bim, Bid, Puma, Noxa) activating the pro‑apoptotic effectors Bax and Bak. Bax/Bak oligomerize in the outer mitochondrial membrane, causing mitochondrial outer membrane permeabilization (MOMP) and release of cytochrome c. Cytochrome c binds Apaf‑1 in the presence of dATP, forming the apoptosome that recruits and activates caspase‑9. Active caspase‑9 cleaves and activates executioner caspases‑3/7, which dismantle the cell by cleaving substrates such as PARP, lamin A, and ICAD (inhibitor of caspase‑activated DNase), leading to DNA fragmentation. The extrinsic (death receptor) pathway is initiated by ligands (FasL, TNF‑α, TRAIL) binding to their cognate death receptors (Fas/CD95, TNFR1, DR4/5) of the TNF receptor superfamily. Receptor trimerization recruits the adaptor FADD and procaspase‑8 to form the DISC (death‑inducing signaling complex), activating caspase‑8. In type I cells, caspase‑8 directly activates caspase‑3; in type II cells, caspase‑8 cleaves Bid to tBid, engaging the mitochondrial amplification loop. FLIP (FLICE‑inhibitory protein) competes with caspase‑8 at the DISC, providing a regulatory checkpoint. Regulated necrosis pathways execute lytic death with inflammatory consequences. Necroptosis requires RIPK1‑RIPK3‑MLKL signaling: when caspase‑8 is inhibited (e.g., by viral FLIPs), RIPK1 and RIPK3 form the necrosome, phosphorylating MLKL, which translocates to the plasma membrane to form pores. Pyroptosis is driven by inflammasome activation (NLRP3, AIM2, NLRC4) leading to caspase‑1 (canonical) or caspase‑11/4/5 (non‑canonical) cleavage of gasdermin D (GSDMD); the N‑terminal GSDMD fragment forms membrane pores, releasing IL‑1β and IL‑18. Ferroptosis is iron‑dependent, lipid‑peroxide‑driven death suppressed by GPX4 (glutathione peroxidase 4) using glutathione; inhibition of system xc⁻ (cystine/glutamate antiporter) by erastin or direct GPX4 inhibition by RSL3 induces ferroptosis. Clinical relevance: Venetoclax (BCL‑2 inhibitor) treats CLL by priming mitochondria for apoptosis; TRAIL‑receptor agonists failed clinically due to decoy receptors and FLIP upregulation; necroptosis inhibition (necrostatin‑1 targeting RIPK1) protects in ischemia‑reperfusion injury; pyroptosis contributes to septic shock and gout (MSU crystals activate NLRP3); ferroptosis inducers are explored in therapy‑resistant cancers.
DNA Damage Response: Sensor Kinases, Checkpoint Effectors, and Repair Pathway Choice
The DNA damage response (DDR) detects lesions, arrests the cell cycle, and coordinates repair. ATM (ataxia‑telangiectasia mutated) is activated primarily by double‑strand breaks (DSBs) via the MRN complex (Mre11‑Rad50‑Nbs1); ATR (ATM‑ and Rad3‑related) responds to replication stress and single‑stranded DNA coated by RPA, recruited by ATRIP. Both kinases phosphorylate the histone variant H2AX (γH2AX) over megabase domains, creating docking sites for repair proteins. Downstream, ATM/ATR phosphorylate CHK2 and CHK1, respectively. Activated CHK1/2 phosphorylate CDC25 phosphatases (CDC25A for S/G2, CDC25C for G2/M), targeting them for degradation or sequestration, thereby preventing CDK activation and enforcing checkpoint arrest. p53 is stabilized by ATM/ATR‑mediated phosphorylation (Ser15, Ser20) and CHK1/2 phosphorylation (Ser20), blocking MDM2‑mediated degradation; p53 transactivates p21 (CDK inhibitor), GADD45, and pro‑apoptotic genes (PUMA, NOXA). DSB repair pathway choice is governed by 53BP1 versus BRCA1‑CtIP antagonism at resected ends. Non‑homologous end joining (NHEJ) — Ku70/80 binds DNA ends, recruits DNA‑PKcs, processes ends via Artemis, and ligates via XRCC4‑Ligase IV; it is error‑prone, active throughout the cell cycle, and favored in G1. Homologous recombination (HR) requires extensive 5'→3' resection by CtIP‑MRE11‑EXO1/DNA2, generating 3' ssDNA overhangs coated by RPA, then replaced by RAD51 (mediated by BRCA2) to invade a homologous template (sister chromatid in S/G2); HR is high‑fidelity but restricted to S/G2. Alternative end joining (alt‑EJ) uses microhomology, is PARP1‑dependent, and generates deletions. Single‑strand break repair (SSBR) via PARP1‑XRCC1‑Ligase III prevents conversion to DSBs at replication forks. Mismatch repair (MMR) (MutSα/MutLα) corrects replication errors; deficiency causes microsatellite instability (MSI) and Lynch syndrome. Nucleotide excision repair (NER) removes bulky adducts (UV pyrimidine dimers); defects cause xeroderma pigmentosum. Base excision repair (BER) handles small base modifications (oxidation, alkylation). Clinical correlations: ATM mutations cause ataxia‑telangiectasia (radiosensitivity, immunodeficiency, lymphoma predisposition); BRCA1/2 mutations impair HR, conferring breast/ovarian cancer risk and sensitivity to PARP inhibitors (olaparib) via synthetic lethality; CHK1 inhibitors abrogate S/G2 checkpoint, enhancing chemotherapy in p53‑deficient tumors.
Protein Homeostasis: Ubiquitin‑Proteasome System, Autophagy, and the Unfolded Protein Response
Proteostasis networks maintain the folded, functional proteome. The ubiquitin‑proteasome system (UPS) degrades short‑lived, misfolded, or regulatory proteins. Ubiquitin (76 aa) is activated by E1 (ATP‑dependent adenylation), transferred to E2 (conjugating enzyme), and ligated to substrate lysine by E3 ligase (HECT, RING, or RBR families). K48‑linked polyubiquitin chains target substrates to the 26S proteasome (20S core + 19S regulatory particle); the 19S particle recognizes ubiquitin, unfolds substrates via ATPases (Rpt1‑6), and translocates them into the 20S chamber for proteolysis. K63‑linked chains serve non‑degradative roles (DNA repair, signaling). Deubiquitinases (DUBs) (USP, OTU, MJD families) edit chains, rescuing substrates or recycling ubiquitin. ER‑associated degradation (ERAD) retrotranslocates misfolded ER luminal/membrane proteins to the cytosol for UPS degradation: HRD1‑SEL1L and gp78 are major E3s; p97/VCP (AAA+ ATPase) extracts substrates. Autophagy delivers cytoplasmic cargo to lysosomes. Macroautophagy initiates with ULK1 complex (ULK1, ATG13, FIP200, ATG101) activated by AMPK (phosphorylates ULK1 Ser317, Ser777) and inhibited by mTORC1 (phosphorylates ULK1 Ser757). PI3KC3 complex (VPS34, VPS15, Beclin‑1, ATG14L) generates PI3P at the phagophore. Two ubiquitin‑like conjugation systems expand the membrane: ATG12‑ATG5‑ATG16L1 (E3‑like for LC3 lipidation) and LC3/GABARAP family proteins conjugated to phosphatidylethanolamine (LC3‑II) by ATG7 (E1) and ATG3 (E2). Selective autophagy uses receptors (p62/SQSTM1, NBR1, OPTN, NDP52) that bind both ubiquitin on cargo and LC3‑II. Mitophagy (PINK1‑Parkin pathway): depolarized mitochondria accumulate PINK1 on OMM, recruiting Parkin (E3) to ubiquitinate mitochondrial proteins, recruiting autophagy receptors. Unfolded protein response (UPR) senses ER luminal misfolding via three transmembrane sensors: IRE1α (RNase/kinase) splices XBP1 mRNA → XBP1s transcription factor upregulates ERAD, chaperones, lipid synthesis; PERK phosphorylates eIF2α (Ser51) → global translation attenuation but selective translation of ATF4 → CHOP (pro‑apoptotic) and amino acid metabolism genes; ATF6 translocates to Golgi, cleaved by S1P/S2P → cytosolic fragment activates ER quality‑control genes. Chronic ER stress switches UPR from adaptive to apoptotic via CHOP‑mediated Bim induction, caspase‑12 activation (rodents), and IRE1α‑TRAF2‑ASK1‑JNK signaling. Diseases: Proteasome inhibitors (bortezomib, carfilzomib) treat multiple myeloma by blocking NF‑κB activation and inducing ER stress; autophagy defects (ATG mutations) cause neurodegeneration; Parkin/PINK1 mutations cause early‑onset Parkinsonism; UPR dysregulation underlies Wolfram syndrome (WFS1), congenital disorders of glycosylation, and contributes to diabetes (β‑cell ER stress).
Cell‑Cell Junctions, Adhesion Molecules, and Extracellular Matrix Remodeling
Multicellular organization relies on specialized junctions and dynamic ECM interactions. Tight junctions (zonula occludens) seal the paracellular space and maintain apical‑basal polarity. Transmembrane proteins claudins (pore‑forming or barrier‑forming), occludin, trICellulin, and JAMs interact homotypically/heterotypically; cytoplasmic plaque proteins ZO‑1/2/3 (MAGUK family) link to actin via cingulin, afadin, and myosin. Adherens junctions (zonula adherens) mediate strong adhesion via E‑cadherin (classical cadherin) homophilic binding; cytoplasmic tail binds β‑catenin (armadillo protein), which binds α‑catenin; α‑catenin recruits vinculin and formin‑1 to nucleate actin. Desmosomes provide tensile strength: desmoglein/desmocollin (cadherin family) bind plakoglobin and plakophilin (armadillo), which recruit desmoplakin linking to intermediate filaments (keratin). Gap junctions allow direct cytoplasmic continuity via connexin hexamers (connexons); permeability regulated by phosphorylation, pH, Ca²⁺. Hemidesmosomes anchor basal epithelium to basement membrane: α6β4 integrin binds laminin‑332; cytoplasmic domain recruits plectin and BP230 linking to keratin. Focal adhesions connect actin stress fibers to ECM via integrins (αβ heterodimers); talin and kindlin activate integrins; FAK autophosphorylates (Tyr397), recruiting Src, paxillin, vinculin, zyxin — linking to actin and signaling (PI3K/Akt, MAPK). ECM composition: Collagens (fibrillar I, II, III, V, XI; network IV; beaded VI; FACIT IX, XII, XIV) provide tensile strength; elastin confers elasticity; proteoglycans (aggrecan, versican, decorin, perlecan) sequester growth factors (FGF, TGF‑β); glycoproteins (fibronectin, laminins, tenascin) mediate cell adhesion. Matrix metalloproteinases (MMPs) (collagenases MMP‑1,8,13; gelatinases MMP‑2,9; stromelysins MMP‑3,10,11; MT‑MMPs) degrade ECM; activity regulated by TIMPs (tissue inhibitors of metalloproteinases). Epithelial‑mesenchymal transition (EMT) involves E‑cadherin repression (Snail, Slug, ZEB1/2, Twist), upregulation of N‑cadherin, vimentin, fibronectin, and MMPs, driven by TGF‑β, Wnt, Notch, and hypoxia (HIF‑1α). Pathology: Pemphigus vulgaris (autoantibodies against desmoglein‑3) causes acantholysis; bullous pemphigoid (anti‑BP180/BP230) disrupts hemidesmosomes; metastatic carcinoma exploits EMT and MMP‑mediated invasion; Marfan syndrome (FBN1 mutation) impairs microfibril assembly, causing aortic dissection; Ehlers‑Danlos syndromes (COL5A1, COL3A1, TNXB) manifest joint hypermobility, skin fragility.
Nuclear‑Cytoplasmic Transport and Transcriptional Control by Chromatin Remodeling
Macromolecular exchange between nucleus and cytoplasm occurs through the nuclear pore complex (NPC), a ~110 MDa assembly of ~30 nucleoporins (Nups) with FG‑repeat domains forming a selective barrier. Importins (karyopherins) bind nuclear localization signals (NLS; classical monopartite/bipartite basic motifs) in the cytoplasm; RanGTP binding in the nucleus triggers cargo release. Exportins (e.g., CRM1/XPO1) bind nuclear export signals (NES; leucine‑rich) cooperatively with RanGTP; cytoplasmic RanGAP‑mediated GTP hydrolysis dissociates the complex. Ran gradient (nuclear RanGTP high, cytoplasmic RanGDP high) is maintained by nuclear RCC1 (RanGEF) and cytoplasmic RanGAP. Transcriptional regulation integrates signaling at chromatin. Histone modifications create docking sites: H3K4me3 (active promoters), H3K27ac (active enhancers), H3K27me3 (Polycomb repression), H3K9me3 (heterochromatin). Writers (HATs: p300/CBP, GCN5; HMTs: MLL/COMPASS for H3K4, EZH2 for H3K27, SUV39H1 for H3K9), erasers (HDACs: class I/II/IV; sirtuins NAD⁺‑dependent; KDMs: LSD1, JmjC domain demethylases), and readers (bromodomains for acetyl‑lysine, chromodomains/PHD fingers for methyl‑lysine) interpret the code. ATP‑dependent chromatin remodelers reposition nucleosomes: SWI/SNF (BAF/PBAF) evicts or slides nucleosomes at enhancers/promoters (mutated in ~20% cancers); ISWI spaces nucleosomes; CHD (NuRD complex) couples remodeling with HDAC activity; INO80/SWR1 exchanges H2A.Z. Enhancer‑promoter looping mediated by cohesin (extrusion) and CTCF (boundary) organizes topologically associating domains (TADs); disruption causes enhancer hijacking in cancer (e.g., MYC activation). Phase separation of transcriptional condensates (mediated by intrinsically disordered regions of Mediator, BRD4, RNA Pol II CTD) concentrates machinery at super‑enhancers. Non‑coding RNAs: lncRNAs (XIST, HOTAIR, MALAT1) scaffold chromatin modifiers; eRNAs mark active enhancers; circRNAs sponge miRNAs. Clinical links: BET inhibitors (JQ1) displace BRD4 from acetylated histones, downregulating MYC in hematologic malignancies; EZH2 inhibitors (tazemetostat) treat EZH2‑mutant follicular lymphoma and SMARCB1‑deficient rhabdoid tumors; XPO1 inhibitor (selinexor) traps tumor suppressors (p53, p21, FOXO) in nucleus; lamin A/C mutations (LMNA) cause progeria and muscular dystrophy by disrupting nuclear mechanics and chromatin organization.
- Confusing the mitochondrial apoptosis checkpoint (Bax/Bak activation) with the death receptor checkpoint (FLIP at DISC); they are distinct regulatory nodes.
- Assuming all DSBs are repaired by HR in S/G2; 53BP1‑Shieldin actively blocks resection, forcing NHEJ even in S phase.
- Treating PARP inhibition as only catalytic inhibition; clinical PARP inhibitors are PARP trappers — the trapped PARP1‑DNA complex is the cytotoxic lesion.
- Overlooking that autophagy can be pro‑survival or pro‑death depending on context; complete blockade (ATG knockout) is lethal, but partial inhibition may sensitize or protect.
- Misassigning UPR sensors: IRE1α splices XBP1, PERK phosphorylates eIF2α, ATF6 is cleaved — each has unique downstream effectors.
- Confusing desmosome (intermediate filament anchor) with adherens junction (actin anchor) or hemidesmosome (basal integrin anchor); each links to a different cytoskeletal system.
- Assuming nuclear import/export uses the same receptor; importins and exportins are distinct karyopherin families with opposite RanGTP dependencies.
These advanced mechanisms integrate cell death, genome maintenance, proteostasis, tissue architecture, and nuclear regulation into a coherent framework that examiners test through pathway‑based reasoning and therapeutic application questions.